Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity Disclosure (Details)

Stockholders' Equity Disclosure (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended	9 Months Ended		1 Months Ended		3 Months Ended	9 Months Ended		9 Months Ended
Stockholders' Equity Disclosure (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014 Series B Preferred Stock	Sep. 30, 2014 Series C Preferred Stock	May 31, 2014 Series D Preferred Stock	Jan. 31, 2014 Series D Preferred Stock	Sep. 30, 2014 Series D Preferred Stock	Sep. 30, 2014 Series D Preferred Stock	Oct. 31, 2013 Series D Preferred Stock	Sep. 30, 2014 2011 Equity Incentive Plan, January 13, 2014	Sep. 30, 2014 2011 Equity Incentive Plan, January 16, 2014	Sep. 30, 2014 2011 Equity Incentive Plan, February 1, 2014	Sep. 30, 2014 2011 Equity Incentive Plan, April 4, 2014	Sep. 30, 2014 2011 Equity Incentive Plan, June 19, 2014	Sep. 30, 2014 2011 Equity Incentive Plan, June 19, 2014 (2)	Sep. 30, 2014 Series D Unit offering	Sep. 30, 2014 Non-public offering of notes and warrants	Sep. 30, 2014 Non-public offering of notes and warrants(2)
Common stock authorized	20,000,000		20,000,000		20,000,000
Common shares issued	8,287,730		8,287,730		8,082,000
Common shares outstanding	8,434,665		8,434,665		8,082,000
Preferred stock authorized	4,500,000		4,500,000		4,500,000
Preferred stock outstanding	883,303		883,303		1,005,648
Preferred shares converted to common shares						101,935	45,000
Accumulated dividends released						$ 40,529
Annual dividend rate							$ 0.16				$ 0.24
Dividends payable							17,870			53,054	53,054
Shares outstanding										883,303	883,303
Units offered (Common Stock and Warrants)												772,352
Units offered (Common Stock and Warrants), price per unit												$ 3.00
Units offered (Common Stock and Warrants), potential proceeds												2,317,056
Units offered (Common Stock and Warrants), additional over-allotment												1,000,000
Units offered (Common Stock and Warrants), potential proceeds for additional over-allotment												3,000,000
Units sold during offering								118,655	53,332
Gross proceeds from units sold in offering								355,966	159,996
Issuance costs									6,000
Dividends paid										49,254	138,937
Original issue price per share										$ 3.00	$ 3.00
Beneficial conversion feature (BCF)											24,279
Number of options granted			298,000		410,000								94,000	40,000	50,000	4,000	10,000	100,000
Stock-based compensation expense	46,133	17,526	209,854	67,219
Unrecognized compensation expense	$ 403,153		$ 403,153
Number of warrants issued																			85,993	283,329	432,995